Zymeworks (ZYME) EBITDA (2021 - 2026)

Zymeworks has reported EBITDA for 6 years, with the latest figure at -$47.1 million in Q1 2026.

• Quarterly EBITDA fell 83.96% year-over-year to -$47.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.1 million (up 8.7% YoY) and the FY2025 annual result came in at -$92.5 million, up 32.5% from the prior year.
• EBITDA fell to -$47.1 million in Q1 2026 per ZYME's latest filing, from -$44.2 million in the prior quarter.
• Over five years, EBITDA peaked at $319.4 million in Q4 2022 and troughed at -$72.7 million in Q1 2022.
• A 5-year average of -$16.7 million and a median of -$34.2 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2023: EBITDA soared 881.89% in 2022, then tumbled 107.33% in 2023.
• Over 5 years, EBITDA stood at $319.4 million in 2022, then plunged by 107.33% to -$23.4 million in 2023, then advanced by 5.14% to -$22.2 million in 2024, then slumped by 98.73% to -$44.2 million in 2025, then slipped by 6.72% to -$47.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$47.1 million, -$44.2 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.